Multiple biomarker 5FU/ capecitabine pharmacogenomic drug safety and treatment management test
EDX Medical is developing a new 5FU/capecitabine safety and treatment management test in collaboration with the University of Oxford.
- The test will be the first and only UK test to fully meet new international guidelines (tier I and II) from The Association for Molecular Pathology (AMP).
- The new multiple biomarker panel is particularly important for identifying risk in ethnic minorities.
- The test includes proprietary markers for cardiac and gastrointestinal adverse reactions, exclusive to EDX Medical.
To develop this test, EDX Medical has entered into an exclusive agreement with Oxford University Innovation Ltd (OUI), to in-license new intellectual property developed by scientists and doctors at Oxford and Birmingham Universities through research funded by Cancer Research UK (CRUK).
This will enable us to develop a much-improved test to determine safety and dose management for individual patients receiving 5-fluorouracil (5-FU), capecitabine and related chemotherapy medications as part of their cancer treatment. These drugs are widely used in the first-line treatment of colorectal cancer, breast cancer and cancers of the upper gastrointestinal tract but carry serious adverse side effects for certain individuals.
The new test will be available exclusively from EDX Medical.
We believe this test has the potential to benefit millions of patients worldwide. More than 10 million people globally receive some form of chemotherapy annually and in England alone, 38,000 patients receive fluoropyrimidine-based chemotherapy each year, each of whom require testing prior to treatment
EDX Medical is developing the new 5FU/capecitabine pharmacogenomic drug safety and treatment management test under the EDX brand as one of several programmes under its strategic collaboration with Thermo Fisher Scientific, EMEA Ltd. (“Thermo Fisher”), a world leading supplier of life sciences solutions and services.
